Antiplatelet and Anticoagulant Therapy in Stroke Prevention in African-Americans

1998 ◽  
pp. 167-179
Author(s):  
M.J. Schneck ◽  
S. Chaturvedi ◽  
D. Thompson ◽  
P.B. Gorelick
Keyword(s):  
African Americans ◽  
Anticoagulant Therapy ◽  
Stroke Prevention

Review of Economics and Cost-Effectiveness Analyses of Anticoagulant Therapy for Stroke Prevention in Atrial Fibrillation in the US

2013 ◽  
Vol 47 (5) ◽  
pp. 671-685 ◽  
Author(s):  
Birgitta von Schéele ◽  
Maria Fernandez ◽  
Susan Lynn Hogue ◽  
Winghan Jacqueline Kwong
Keyword(s):  
Atrial Fibrillation ◽  
Cost Effectiveness ◽  
Anticoagulant Therapy ◽  
Stroke Prevention ◽  
The Us

Abstract W MP4: Psychometric Evaluation of an Instrument to Assess Perceived Benefits and Barriers to Exercise for Stroke Prevention among African Americans

Stroke ◽  
2014 ◽  
Vol 45 (suppl_1) ◽  
Author(s):  
Dawn Aycock ◽  
Patricia Clark
Keyword(s):  
African Americans ◽  
Health Beliefs ◽  
Exercise Performance ◽  
Stroke Prevention ◽  
Reliability And Validity ◽  
Self Report ◽  
Perceived Benefits ◽  
Exercise Participation ◽  
Barriers To Exercise ◽  
Two Factors

Exercise can reduce the risk of stroke and identifying perceived benefits and barriers to exercise relevant to African Americans (AA) may contribute to ways to facilitate exercise participation. However, standardized instruments to assess exercise beliefs for stroke prevention have not been well tested in AA. Purpose: To examine the psychometric properties of the Exercise Benefits and Barriers for Stroke Prevention Scale (EBBSP), a combination of the perceived benefits and barriers subscales from the Cerebrovascular Attitudes and Beliefs Scale - Revised and the Health Beliefs Related to Cardiovascular Disease Scale, adapted for stroke. Methods: A non-random sample of 66 at risk, young to middle-aged AA completed the EBBSP, a 16-item self-report, 5-point Likert scale. Cronbach's alpha procedure tested reliabilities and principal components analysis with varimax rotation was employed to assess construct validity. Self-report measures of current exercise performance and future intentions to exercise were administered and Spearman Rho analyses were used to examine predictive validity. Results: Cronbach’s reliability coefficients for the benefits and barriers subscales were 0.82 and 0.76. The Kaiser-Meyer-Olkin measure (0.69) and Bartlett’s test (p= .000) indicated the data were adequate to be factored. A four factor solution explained 64% of the common variance. Two factors pertained to benefits (i.e. health and support/resources) and two factors applied to barriers (i.e. sensory and time priority). Perceived health benefits explained the majority of the variance (33%), consistent with the most commonly reported motivator to exercise, “good/better health” (34%). Greater benefits to exercise was associated with greater future intentions to exercise (r s = 0.60, p< 0.01) but not with current exercise performance (p > 0.05), while fewer barriers to exercise was associated with higher exercise performance (r s = -0.25, p< .05) and greater future intentions to exercise (r s = -.29, p< .05). Conclusion: The p sychometric evaluation of the EBBSP revealed preliminary evidence of acceptable reliability and validity. The EBBSP may be useful in research with a focus on understanding, prediction, and promotion of exercise for stroke prevention among AA.

Advances in Atrial Fibrillation-related Stroke Prevention

2015 ◽  
Vol 9 (2) ◽  
pp. 122
Author(s):  
Pierre Amarenco ◽  
Werner Hacke ◽  
Bo Norrving ◽  
Natalia Rost ◽  
◽  
...  
Keyword(s):  
Risk Factors ◽  
Atrial Fibrillation ◽  
Anticoagulant Therapy ◽  
Stroke Prevention ◽  
Stroke Risk ◽  
Oral Anticoagulants ◽  
Factor Xa ◽  
Haemorrhagic Stroke ◽  
Bleeding Events ◽  
Patients At Risk

In patients with atrial fibrillation (AF) the risk of stroke is substantially increased, especially in those who are elderly (over 75 years) or have risk factors such as previous stroke, heart failure or hypertension. Stroke outcomes are also generally much worse in those with AF. Current guidelines indicate that any patient with AF and risk factors for stroke should receive anticoagulant therapy to limit their stroke risk. Despite these established recommendations, only 50 % of patients at risk receive anticoagulation with a vitamin K antagonist (VKA) and only 50 % of those are within the therapeutic range, indicating lack of adherence to the guidelines. Withholding anticoagulant therapy is mainly left to an individual physician’s choice, as shown in the ongoing GARFIELD registry of AF stroke prevention practice. Many physicians fear the risk of intracranial haemorrhage (ICH) for which outcomes remain poor. Recent clinical studies have shown that the non-VKA oral anticoagulants (NOACs) (apixaban, rivaroxaban, dabigatran and edoxaban) significantly reduce the risk of ICH and other bleeding events, while having non-inferior stroke prevention to warfarin. Use of these drugs, limiting exposure to aspirin and alcohol and controlling blood pressure have been shown to minimise ICH risk in large clinical trials and meta-analyses. Recent data from the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation (ENGAGE AF)-TIMI 48 study showed that the factor Xa inhibitor edoxaban was non-inferior to well-managed warfarin for reducing all stroke risk, and significantly reduced haemorrhagic stroke, major bleeding, ICH and death. These findings further support the case for using NOAC therapy for stroke prevention in patients with AF and risk factors for stroke.

Stroke Knowledge and Barriers to Stroke Prevention Among African Americans: Implications for Health Communication

2003 ◽  
Vol 8 (4) ◽  
pp. 369-381 ◽  
Author(s):  
CHARLOTTE A. PRATT ◽  
LOUISA HA ◽  
STEVEN R. LEVINE ◽  
CORNELIUS B. PRATT
Keyword(s):  
African Americans ◽  
Health Communication ◽  
Stroke Prevention ◽  
Stroke Knowledge

scholarly journals Anticoagulant therapy for stroke prevention in CKD patients

Nosotchu ◽  
2016 ◽  
Vol 38 (6) ◽  
pp. 449-454
Author(s):  
Makoto Nakajima ◽  
Masaki Watanabe ◽  
Yukio Ando
Keyword(s):  
Anticoagulant Therapy ◽  
Stroke Prevention
Sign in / Sign up

Export Citation Format

Share Document